home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
Post navigation
Previous Post
Previous
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
Next Post
Next
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights